Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
NVQ401
- Development stage
- Preclinical
- Lead developer
- NeuVasQ
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Administration
- Ophthalmic
01
Overview
NVQ401 is a first-in-class bispecific antibody developed by Neuvasq Biotechnologies for the treatment of retinal vascular diseases, including diabetic macular edema (DME) and wet age-related macular degeneration (wAMD). The drug selectively activates the Wnt/β-catenin signaling cascade by targeting G protein-coupled receptor 124 (GPR124) and Low-density lipoprotein receptor-related protein 6 (LRP6), which are essential for maintaining and repairing the blood-retinal barrier. In preclinical studies, NVQ401 has demonstrated the ability to reverse VEGF-induced vascular permeability and reduce both neovascularization and avascular areas. Its potent activation of Wnt receptor signaling suggests potential for quarterly dosing, offering a potentially more durable treatment option compared to current anti-VEGF therapies.
- Other names
- Gpr124/Lrp6-targeting bispecific antibody
02
Targets
ADGRA2LRP6 (Low-density lipoprotein receptor-related protein 6)
Beyond the preview
Go deeper on NVQ401.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on NVQ401.